# Treatment Options for Cardiac Amyloidosis
The treatment of cardiac amyloidosis depends heavily on the type (AL or ATTR) and stage of the disease. In recent years, multiple medications have become available that can slow progression. The goals are usually: to suppress the underlying process, protect heart function, and relieve symptoms.
Medications that inhibit amyloid production or breakdown
Transthyretin (ATTR) Amyloidosis
**Tafamidis**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This medication stabilizes the transthyretin protein, slowing amyloid production. It is used for both hereditary (mutant-ATTR) and acquired (wild-type ATTR) cardiac amyloidosis. In clinical trials, tafamidis slowed the decline in heart function and improved physical functioning. Many patients take it long-term.
Known side effects are usually mild: nausea, diarrhea, and peripheral swelling occur, but serious side effects are rare.
**Acoramidis**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a more recent transthyretin stabilizer. Studies show that acoramidis can reduce heart failure-related hospitalizations and reduce mortality in patients with ATTR cardiomyopathy. It works the same way as tafamidis, but has shown slightly more favorable effects in some studies.
Side effects are similar to tafamidis, including digestive problems and body swelling.
AL (Light-Chain) Amyloidosis
**Bortezomib (optionally with cyclophosphamide and dexamethasone)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a proteasome inhibitor that targets immune cells producing abnormal light chains. Bortezomib is often given in combination with other medications. It can significantly reduce the amount of abnormal proteins in the blood and sometimes even improve heart function.
Side effects can include neuropathy (nerve pain, especially in feet and hands), fatigue, infections, and low platelet counts. The combination with chemotherapy carries additional risks.
**Daratumumab**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a monoclonal antibody directed against CD38, a protein on plasma immune cells. Daratumumab helps eliminate these abnormal cells. It is increasingly used as part of combination regimens for AL amyloidosis of the heart.
Possible side effects include reactions at the site of intravenous administration, infections, and fatigue.
**Dexamethasone (short-term)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Short-term administration of this corticosteroid can help reduce inflammatory reactions in the early stage and strengthen the chemotherapy effect. Recent research suggests that long-term use, however, causes more harm than benefit in newly diagnosed AL amyloidosis.
Side effects increase with longer use and include elevated inflammation, susceptibility to infection, and changes in glucose metabolism.
**Melphalan with Autologous Stem Cell Transplantation**
ProveniIncluded in official guidelines, or approved by EMA or FDA
In AL amyloidosis, melphalan (a chemotherapy drug) followed by stem cell transplantation can be an intensive, curative strategy. The stem cells subsequently restore the immune system. This is an aggressive approach suitable only for selected, healthy patients.
Side effects are severe and can include infections, bleeding, organ damage, and prolonged recovery time.
SGLT2 Inhibitors (Sodium-Glucose Cotransporter 2 Inhibitors)
ResearchediPositive results in clinical studies, not yet standard treatment
Medications such as empagliflozin and dapagliflozin were originally developed for diabetes, but have been shown to counteract heart failure in amyloidosis. They improve the energy efficiency of heart muscle cells and can reduce fluid accumulation.
Recent meta-analyses suggest that these medications can improve heart function and exercise capacity in both ATTR and AL amyloidosis. They generally have mild side effects: occasional urinary tract infections and mild dehydration.
Supportive Cardiac Treatments
ACE Inhibitors and ARB (Angiotensin II Receptor Blockers)
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medicines are used to regulate blood pressure and relieve the heart. They prevent further damage to heart tissue.
Possible side effects include cough, dizziness and elevated potassium levels in the blood.
Beta blockers
ProveniIncluded in official guidelines, or approved by EMA or FDA
They slow the heart rate and reduce the workload of the heart. In amyloidosis, careful dosing is necessary because the heart is stiffer and cannot respond as quickly.
Side effects can include fatigue, low blood pressure and worsening circulation in the limbs.
Diuretics
ProveniIncluded in official guidelines, or approved by EMA or FDA
These fluid-reducing agents help reduce fluid accumulation in the lungs and tissues, which decreases shortness of breath.
Side effects include low potassium and sodium levels in the blood, weakness and dizziness.
Digoxin
ProveniIncluded in official guidelines, or approved by EMA or FDA
This old heart medicine strengthens the heartbeat and slows the heart rhythm. It is used carefully in amyloidosis because of the narrow therapeutic window and interactions with other medications.
Side effects can include arrhythmias and toxicity if levels become too high.
Treatment of atrial fibrillation
**Antithrombotic agents (blood thinners)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients with cardiac amyloidosis develop irregular heartbeat (atrial fibrillation). Blood thinners such as DOACs (direct oral anticoagulants) or warfarin prevent blood clots that can cause stroke.
Side effects depend on the type: for DOACs, bleeding is the main risk.
**Rhythm management agents**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Amiodarone and other antiarrhythmic medicines can help make the heart rhythm more regular. They are used carefully because of potential long-term side effects.
Newer and experimental directions
**Selinexor with daratumumab and dexamethasone (XDd regimen)**
ResearchediPositive results in clinical studies, not yet standard treatment
Selinexor is a selective nuclear export inhibitor that changes how immune cells function. It is being investigated in combination with daratumumab for AL cardiac amyloidosis. Early results are promising for patients with aggressive disease.
**Tolcapone**
ExperimentaliOngoing in study setting, outcome still unknown
This medicine is being investigated for rare forms of hereditary ATTR amyloidosis with nerve involvement. A single case comparison showed long-term stabilisation of symptoms.
**PET and hybrid imaging techniques**
ResearchediPositive results in clinical studies, not yet standard treatment
18F-florbetaben PET is an imaging method that can directly visualise amyloid accumulation and helps with diagnosis and monitoring of therapy effectiveness. This examination is not yet standard in all centres.
Supportive and palliative measures
Regardless of the type of amyloidosis, regular cardiac monitoring, fluid restriction and salt restriction help control symptoms such as shortness of breath and swelling. Some patients benefit from rehabilitation or inspiratory muscle exercises. Psychological support can be valuable given the serious diagnosis.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._